When regulators knew more than they told: The untold story of mRNA vaccine biodistribution

06/03/2026 / By Willow Tohi

Regulators knew mRNA COVID vaccines could travel beyond the injection site to liver, spleen and other organs, but public messaging claimed they stayed “in the arm” and vanished within hours or days.
Internal regulatory documents from Australia’s TGA and Europe’s EMA showed biodistribution data revealing systemic trafficking before vaccines were authorized, yet this information was not broadly disclosed.
Peer-reviewed studies published after rollout detected vaccine mRNA and spike protein in blood up to 28 days and in cardiac tissue up to 30 days post-vaccination, contradicting early public assurances.
A 2025 Yale investigation into post-vaccination syndrome found elevated circulating spike protein months after vaccination in some symptomatic individuals, suggesting possible long-term antigen persistence.
The discrepancy between what regulators knew and what the public was told raises serious questions about informed consent, negligent misrepresentation and potential legal liability.

This month, a comprehensive investigation by TrialSite News has revealed that regulators reviewing COVID-19 mRNA vaccines possessed data showing these products could travel throughout the body—yet the public was consistently told the vaccines stayed “in the arm” and disappeared within a day or two.

This revelation, which came as Health and Human Services Secretary Robert F. Kennedy Jr. was tasked with investigating vaccine safety, represents a pivotal moment in understanding what millions of Americans were not told about the biological fate of the mRNA technology they received. The question of why, who, when, where and what happened centers on regulatory agencies in the United States, Australia and Europe that reviewed animal and human data before emergency authorization, but chose to communicate a simplified narrative that did not reflect the science they had in hand.

What regulators saw before the public

By January 2021, Australia’s Therapeutic Goods Administration had already written that Pfizer/BioNTech’s platform localized antigen expression “mainly” to the injection site, liver and likely draining lymph nodes, with near-complete degradation in nine days. That same report described radiolabeled lipid nanoparticle uptake in the injection site and liver, with lower distribution in the spleen, adrenal glands and ovaries, and noted clinical signs that “might indicate toxicity” at high doses in rats. The European Medicines Agency’s assessment report for Moderna’s vaccine was similarly revealing. It accepted biodistribution data from a different SM-102 LNP vaccine rather than a dedicated study for mRNA-1273, and stated that the mRNA platform was distributed throughout the body—including low levels in brain, heart, lung, eye and testis—with liver distribution being “evident.” The report also noted that no dedicated absorption, metabolism and excretion studies had been submitted for the Moderna product.

These findings were consistent with earlier scientific literature. A 2015 study by Pardi and colleagues reported that intramuscular mRNA-LNP delivery could traffic systemically and produce active translation in the liver for one to four days. By 2018, researchers had written that MC3-based LNP toxicities were associated with cytokine and complement activation. In 2019, Moderna-linked work on intramuscular mRNA vaccines found that liver and spleen lipid levels closely followed levels at the injection site. The field already understood that lipid nanoparticle delivery changed the pharmacology—and with it, the safety questions.

The public received a different story

While regulators reviewed this evidence, public-facing messaging remained far more categorical. In July 2021, a University of Alabama at Birmingham vaccine researcher told the public that vaccines are “quickly eliminated” and that this is “particularly true” of mRNA vaccines. In March 2022, the U.S. Department of Veterans Affairs told patients that vaccine mRNA lasts “a day or two” and the protein only “a few weeks.” In late 2022, Nebraska Medicine stated there was “no evidence” of organ accumulation, that mRNA is degraded “within a few days,” and that vaccines mostly remain near the injection site and local lymph nodes. Even the Centers for Disease Control and Prevention’s 2024 explainer continued to reduce the story to mRNA entering muscle cells, making spike protein, and then being broken down and removed as waste.

This messaging relied on an older scientific shorthand: endogenous and naked mRNA are fragile and short-lived. But that shorthand became misleading once COVID-19 vaccines used chemically modified mRNA packaged in lipid nanoparticles. Those delivery systems changed where the payload traveled and how long it persisted. The public was told an average-case narrative that blurred the difference between naked cellular mRNA and LNP-formulated, nucleoside-modified therapeutic mRNA.

Human evidence later contradicted official narratives

Since rollout, human data have pushed the field toward a more honest position. Vaccine mRNA has been reported in blood at 15 days after vaccination. Full-length or trace sequences have been found in blood up to 28 days. Vaccine material has been detected in the heart up to 30 days in recently vaccinated decedents. A 2022 Cell paper reported that mRNA vaccination stimulated germinal centers containing vaccine mRNA and spike antigen for up to eight weeks in some cases. A 2023 study led by Krauson found SARS-CoV-2 vaccine mRNA and spike protein could persist up to 30 days post-vaccination and be detected in cardiac tissue. Meanwhile, long COVID research has demonstrated viral spike protein fragments persisting in tissues up to 14 months, and in some reports nearly two years, after infection.

A 2025 Yale-associated investigation into post-vaccination syndrome reported elevated circulating spike protein in some symptomatic individuals months after vaccination, suggesting possible persistent antigen exposure in at least a subset of cases. While persistence does not automatically prove toxicity or ongoing disease causation, a growing number of physicians and scientists are certain that lingering spike protein can lead to adverse reactions in the body.

The history of vaccine safety claims

This situation echoes earlier episodes in vaccine history where initial assurances did not match later evidence. When the original oral polio vaccine was introduced in 1955, it used a weakened form of the poliovirus that in rare cases became activated and caused paralysis. Those cases occurred between one and four weeks after vaccination. In 1976, a swine flu vaccine was identified in rare cases as a cause of Guillain-Barré Syndrome, with almost all cases occurring in the eight weeks after vaccination. COVID-19 vaccines have similarly been linked to side effects: About one in 100,000 people receiving the AstraZeneca vaccine experienced a clotting disorder, while myocarditis has been widely reported in conjunction with Pfizer and Moderna vaccines.

The difference is scale and the nature of the claims made. With COVID-19 vaccines, regulators and public health officials made categorical statements about biodistribution that exceeded the available evidence. A 2022 study by Fertig and colleagues reported detectable vaccine-associated mRNA in blood circulation for at least 15 days after vaccination. A 2023 review titled “Biodistribution of RNA Vaccines and of Their Products” summarized evidence that lipid nanoparticle-encapsulated mRNA and translated spike protein can distribute beyond the injection site into lymphatic tissue, liver, spleen and other organs.

These findings complicate early pandemic-era assurances that spike protein and mRNA products remain strictly localized and are rapidly eliminated within hours or days.